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Abstract Renal dysfunction is an independent predictor
for cardiovascular morbidity and mortality. We investi-
gated whether chronic hepatitis C virus (HCV) infection
and the related insulin resistance/hyperinsulinemia influ-
ence renal function in comparison with a group of healthy
subjects and with another group with metabolic syndrome.
We enrolled 130 newly diagnosed HCV outpatients mat-
ched for age and gender with 130 patients with metabolic
syndrome and 130 healthy subjects. Renal function was
evaluated by calculation of glomerular filtration rate (e-
GFR, mL/min/1.73 m2) using the CKD-EPI equation. The
following laboratory parameters were measured: fasting
plasma glucose and insulin, total, LDL- and HDL-choles-
terol, triglyceride, creatinine, and HOMA to evaluate
insulin sensitivity. HCV patients with respect to both
healthy subjects and metabolic syndrome patients have a
decreased e-GFR: 86.6 ± 16.1 vs 120.2 ± 23.1 mL/min/
1.73 m2 (P\ 0.0001) and 94.9 ± 22.6 mL/min/1.73 m2
(P = 0.003), respectively. Regarding biochemical
variables, HCV patients, in comparison with healthy sub-
jects, have a higher triglyceride level, creatinine, fasting
insulin and HOMA (3.4 ± 1.4 vs 2.6 ± 1.3; P\ 0.0001).
At linear regression analysis, the correlation between
e-GFR and HOMA is similar in the metabolic syndrome
(r = -0.555, P\ 0.0001) and HCV (r = -0.527,
P\ 0.0001) groups. At multiple regression analysis,
HOMA is the major determinant of e-GFR in both groups,
accounting for, respectively, 30.8 and 27.8 % of its varia-
tion in the metabolic syndrome and HCV. In conclusion,
we demonstrate that HCV patients have a significant
reduction of e-GFR and that insulin resistance is the major
predictor of renal dysfunction.
Keywords Chronic C hepatitis  Renal function  Insulin
resistance  Cardiovascular risk  Metabolic syndrome
Introduction
Chronic hepatitis C virus (HCV) infection is associated
with several metabolic alterations that contribute to
development of subclinical cardiovascular disease, partic-
ularly atherosclerotic vascular damage [1–4]. In accor-
dance with this, we recently demonstrate that
hyperinsulinemia HCV-related is associated with both
increased cardiac mass and arterial vascular stiffness, that
are considered independent and strong predictors of car-
diovascular events also in different settings of patients [5–
8].
In addition, the metabolic syndrome (MS), characterized
by visceral obesity and insulin resistance (IR), is associated
with a decrease in renal function that also represents an
independent and strong predictor of cardiovascular mor-
bidity and mortality in the general population [9, 10]. In
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particular, the National Health and Nutrition Examination
Survey (NHANES) III, demonstrates a strong association
between the MS and the development of chronic kidney
disease (CKD); while, data reported by the Atherosclerosis
Risk in Communities Study (ARIC) demonstrates a strong
correlation between IR status and loss of renal function [11,
12].
On the other hand, there is conflicting evidence about
the possible association between HCV infection and CKD;
particularly, the majority of these studies fail to show an
association between these two clinical conditions [13–16].
Taken together, the aim of this study was to evaluate the
possible association between chronic HCV infection-re-
lated IR and renal dysfunction in comparison with both
healthy subjects and MS patients.
Methods
Study population
For this aim, we designed a cross-sectional study involving
patients evaluated at the University Hospital of Catanzaro.
We recruited 130 HCV? normotensive Caucasian outpa-
tients (75 males and 55 females, mean age
55.2 ± 13.9 years). They were matched for age and gender
in a 1:1:1 ratio with 260 subjects participating in the
CAtanzaro MEtabolic RIsk factors Study (CATAMERIS),
with 130 patients with MS (mean age 54.6 ± 10.3 years)
evaluated according NCEP-ATP III criteria [17] and 130
healthy subjects (mean age 54.4 ± 11.9 years) [18]. At the
time of the first evaluation, both HCV? and MS patients
were newly diagnosed and untreated with antiviral therapy
or other drugs. In the whole study population, exclusion
criteria were type 2 diabetes (T2D) detected by an oral
glucose tolerance test, according to ADA guidelines; his-
tory or clinical evidence of previous cardiovascular events,
administration of any drugs interfering with glucose
metabolism or renal function; kidney, thyroid, endocrine
and advanced liver diseases, transplanted patients, history
of malignant disease; history of chronic abuse of alcohol
([40 g/die) or recreational drugs. None of HCV patients
had liver cirrhosis, detected by clinical and ultrasound
examinations. In addition, in these patients we excluded
membranoproliferative glomerulonephritis by 24-h pro-
teinuria and cryoglobulinemia.
We performed measurements of height and weight
according to a standardized protocol, and body mass index
(BMI) was calculated as kilograms per square meter. The
Ethics Committee approved the protocol and informed
written consent was obtained from all participants. All the
investigations were performed in accordance with the
principles of the Declaration of Helsinki.
Blood pressure measurements
Readings of clinic blood pressure (BP) were obtained in the
left arm of the supine patients, after 5 min of quiet rest,
with a mercury sphygmomanometer. A minimum of three
BP readings were taken on three separate occasions at least
2 weeks apart. Systolic and diastolic BP were recorded at
the first appearance (phase I) and the disappearance (phase
V) of Korotkoff sounds. Baseline BP values were the
average of the last two of the three consecutive measure-
ments obtained at intervals of 3 min. Patients with a clinic
systolic BP (SBP) \130 mmHg and diastolic BP (DBP)
\80 mmHg were defined as normotensives.
Laboratory determinations
All laboratory measurements were performed after 12 h of
fasting. Plasma glucose was determined immediately by
the glucose oxidation method [Glucose analyzer, Beckman
Coulter, Milan; intra-assay coefficient of variation (CV)
2.2 %, inter-assay CV 3.8 %]. Serum insulin was deter-
mined in duplicate by a highly specific radioimmunoassay
using two monoclonal antibodies; intra-assay CV 2.1 %,
inter-assay CV 2.9 %. Total, low-density lipoprotein-
(LDL), and high-density lipoprotein- (HDL) cholesterol
and triglyceride concentrations were measured by enzy-
matic methods (Roche Diagnostics GmbH, Mannheim,
Germany). Quantitative HCV-RNA was assayed by a real-
time polymerase chain reaction assay.
Insulin resistance evaluation
IR was estimated by homeostasis model assessment
(HOMA) according to the following equation:
HOMA = [insulin (lU/ml 9 glucose (mmol/l)]/22.5 [19].
Renal function evaluation
Creatinine was measured by using Jaffe methodology.
Values of estimated glomerular filtration rate (e-GFR, mL/
min/1.73 m2) were calculated by using the equation pro-
posed by investigators in the chronic kidney disease epi-
demiology (CKD-EPI) collaboration [20].
Statistical analysis
ANOVA for continuous clinical and biological data was
performed to test the differences among groups, and the
Bonferroni post hoc test for multiple comparisons was
further performed; for dichotomic variables we used the X2
test. Data are expressed as mean ± SD, and binary data as
percent frequency. Linear regression analysis was per-
formed to correlate e-GFR with the following covariates:
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age, BMI, waist, SBP, DBP, pulse pressure (PP), LDL- and
HDL-cholesterol, triglyceride, fasting plasma glucose and
insulin, HOMA and uric acid. Subsequently, to define the
independent predictors of renal function, variables reaching
statistical significance, were inserted in a stepwise multi-
variate linear regression model. In this one, to avoid a
possible colinearity, we did not include age, fasting glucose
and insulin, but we considered only HOMA. Correlational
analysis was performed in the whole study population and
in the three groups separately. Differences were assumed to
be significant at P\ 0.05. All calculations were done with
a standard statistical package (SPSS for Windows version
20.0, Chicago, IL, USA).
Results
Study population
Clinical and laboratory characteristics of the study popu-
lation are reported in Table 1. There were no significant
differences among groups for age, gender, smoking and
heart rate. Of interest, HCV? patients, with respect to both
healthy and MS subjects show a lower and significant
(P\ 0.0001) e-GFR (Fig. 1). In addition, regarding other
biochemical variables, HCV? patients, in comparison with
healthy subjects, have higher triglyceride level, creatinine,
fasting insulin and HOMA, and lower BMI, total and HDL-
cholesterol.
On the contrary, HCV? patients in comparison with the
MS group have a lower BMI, waist circumference, systolic
and diastolic BP, cholesterol, triglyceride, and fasting
glucose. Of interest, no significant differences are found in
fasting insulin and HOMA values (3.7 ± 1.4 vs 3.4 ± 1.4;
P = 0.287).
In HCV? patients the mean value of HCV-RNA was
3579 ± 1710 9 103 (UI/ml).
Correlational analysis
A linear regression analysis was performed to test the
correlation between e-GFR and different covariates in the
whole study population and in the three groups separately
(Table 2). In the whole study population, e-GFR is sig-
nificantly correlated with HDL-cholesterol and inversely
with age, waist circumference, SBP, DBP, PP, triglyceride,
fasting glucose, insulin, HOMA and uric acid. In the MS
and HCV? groups, e-GFR is statistically correlated with
age, waist circumference, HDL cholesterol, uric acid,
fasting glucose, insulin and HOMA. In addition, in the MS
group, the other covariates that correlate with e-GFR are:
SBP and pulse pressure.
A stepwise multivariate linear regression analysis was
performed to evaluate the independent predictors of e-GFR
in the entire population and in the three different groups
(Table 3). In the whole population, as well as in MS and
HCV? groups, HOMA is the major predictor of e-GFR,
accounting for 25.8, 30.8 and 27.8 % of its variation,
respectively. Of interest, 1 unit of HOMA increase pro-
duces a reduction of -6.062 ml/min/1.73 m2 in MS group
and of -3.155 ml/min/1.73 m2 in HCV? patients. In the
whole population, other independent predictors of e-GFR
are HDL cholesterol, uric acid and waist circumference,
accounting for, respectively, another 9.4, 3.5 and 1.2 % of
its variation. In the MS group, the other covariates retained
in the model are uric acid, waist circumference, gender and
HDL cholesterol accounting for, respectively, 10.3, 5.4, 4.3
and 2.4 % of e-GFR variation. In the HCV? group,
covariates retained in the final model are gender, waist
circumference, uric acid and HDL cholesterol accounting
for, respectively, another 11.6, 10.5, 2.6 and 1.6 % of its
variation.
Discussion
The results of this study demonstrate that HCV? patients,
in comparison with healthy subjects and MS patients, have
a significant decrease in e-GFR. These results have a
clinical relevance because they help to clarify the patho-
genetic role of HCV infection in promoting renal damage
in a group of newly diagnosed HCV? patients without
membranoproliferative glomerulonephritis or cryoglobu-
linemia, all established factors affecting renal function in
this clinical setting. Contrary to other previously published
studies, aimed at demonstrating an association between
HCV infection and CKD, our data emphasize the early role
of viral infection on renal function decrease, also in
patients with still preserved renal function; this condition
has a clinical relevance because it should alert physicians
to routinely evaluate renal function in these patients [13–
16, 21, 22]. Thus, on the basis of this evidence, we
hypothesize that early detection of a loss of renal function
may be useful in slowing the progression to CKD by
appropriate therapeutic interventions. The large sample
size and detailed characterization of patients confer to our
study a very important clinical and biological plausibility
that contributes to clarify the association between HCV
infection and reduction of renal function, similar to that
observed for other subclinical organ damages [5, 6].
Another important finding obtained by our study con-
sists in the fact that IR is a primary and independent pre-
dictor of e-GFR variation in both HCV? and MS patients,
as already reported [11, 12]. The interaction between
metabolic and hemodynamic parameters may be explained
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by previously published data demonstrating that functional
GFR reduction is inversely related to circulating IGF-1
levels [23]. In fact, there is evidence that low IGF-1 levels
impair vasodilating properties of renal arterioles that
decrease both renal blood flow and GFR. This evidence is
explained by our and other data demonstrating that a
dynamic balance exists between IR-related hyperinsuline-
mia and IGF-1 levels [24–26]. In accordance with this, it is
clearly demonstrated that endogenous IGF-1 levels
improve GFR by stimulating the glomerular L-arginine-
nitric oxide pathway, without any systemic hemodynamic
changes [27, 28].
It is well established that visceral obesity is character-
ized by an IR status; in fact, there is growing evidence
demonstrating that a selective excess of visceral adipose
tissue is associated with a higher risk to develop IR because
it acts as an endocrine organ that produces several sub-
stances involved in the regulation of metabolic, inflam-
matory and immune responses [29, 30]. In keeping with
this, it is not surprising that MS patients develop an IR that
may be considered the common soil for metabolic and
hemodynamic alterations that produce the definition of this
syndrome, and that may promote the associated target
organ damage. In accordance with this, the presence of a
MS entails a twofold increased risk for microalbuminuria,
an early indicator of renal damage [31]. In HCV? patients,
it has been demonstrated that the IR degree may be
explained through a direct interaction between viral prod-
ucts and the insulin signaling pathway via IRS-1-PI3-ki-
nase-Akt [32–34]. The biological plausibility of this
finding is also supported by the present results demon-
strating that HOMA is the major determinant of e-GFR
decrease in MS and HCV? patients, accounting for 30.8
and 27.8 % of its variation, respectively. In addition,
HCV? patients, in comparison with healthy subjects, while
presenting a significant lower BMI, show an increased,
although not significant, waist circumference. This is the
second independent predictor of e-GFR accounting for
10.5 % of its variation.
Interestingly, all these conditions interact between them
in promoting the e-GFR reduction with important clinical
implications, considering that the loss of renal function is
an independent predictor of cardiovascular morbidity and
mortality [9, 10]. For these reasons CKD is a relevant
health problem not only in the specific setting of patients
but also in the general population..
Fig. 1 We graphically reported estimated glomerular filtration rate
(e-GFR) mean values in all three different study groups. HCV?
patients presented a significantly lower e-GFR in comparison with
both healthy subjects and metabolic syndrome (MS) patients
(P\ 0.0001, by ANOVA)
Table 2 Linear regression analysis between e-GFR and different covariates in the whole study population and in the three groups
All (n = 390) Healthy (n = 130) MS (n = 130) HCV? (n = 130)
r P r P r P r P
Age, years -0.265 \0.0001 -0.257 0.002 -0.196 0.013 -0.516 \0.0001
BMI, kg/m2 0.038 0.230 -0.055 0.267 -0.027 0.379 0.008 0.465
Waist, cm -0.283 \0.0001 -0.147 0.048 -0.351 \0.0001 -0.380 \0.0001
Systolic BP, mmHg -0.167 \0.0001 -0.0201 0.410 -0.328 \0.0001 0.043 0.313
Diastolic BP, mmHg -0.094 0.032 -0.014 0.438 0.037 0.336 -0.033 0.356
PP, mmHg -0.146 0.002 -0.013 0.440 -0.389 \0.0001 0.080 0.183
LDL Cholesterol, mg/dl -0.081 0.055 -0.342 \0.0001 -0.080 0.182 0.090 0.153
HDL Cholesterol, mg/dl 0.433 \0.0001 0.144 0.052 0.384 \0.0001 0.341 \0.0001
Triglyceride, mg/dl -0.137 0.003 -0.099 0.132 -0.001 0.494 0.049 0.289
Fasting glucose, mg/dl -0.294 \0.0001 -0.119 0.089 -0.279 0.001 -0.340 \0.0001
Fasting insulin, lUI/ml -0.468 \0.0001 -0.259 0.001 -0.514 \0.0001 -0.472 \0.0001
HOMA -0.508 \0.0001 -0.273 0.001 -0.555 \0.0001 -0.527 \0.0001
Uric acid, mg/dl -0.360 \0.0001 -0.266 0.001 -0.444 \0.0001 -0.407 \0.0001
MS metabolic syndrome, BMI body mass index, BP blood pressure, PP pulse pressure, LDL low density lipoprotein, HDL high density
lipoprotein, e-GFR estimated glomerular filtration rate, HOMA homeostasis model assessment
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Study limitation
These data are associative, and do not definitively support
regarding the role of metabolic alterations in promoting
renal dysfunction.
Recently, new drugs are reported to be able to counteract
HCV replication and limit the progression of liver disease
with a high likelihood of healing. However, at this moment,
no data are available regarding the impact ofmicrobiological
healing on extrahepatic clinical manifestations, which con-
tribute to morbidity and mortality in these patients.
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